What is the recommended CAPOX (capecitabine plus oxaliplatin) regimen for a chemotherapy‑naïve patient with metastatic sigmoid colon cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CAPOX Regimen for Metastatic Sigmoid Colon Cancer

For a chemotherapy-naïve patient with metastatic sigmoid colon cancer, CAPOX (capecitabine plus oxaliplatin) is a well-established first-line treatment option that has demonstrated non-inferiority to FOLFOX with similar efficacy and a more convenient administration schedule.

Standard CAPOX Dosing Regimen

The recommended dosing schedule based on FDA labeling and international guidelines 1:

  • Oxaliplatin: 130 mg/m² IV infusion over 2 hours on Day 1
  • Capecitabine: 1,000 mg/m² orally twice daily on Days 1-14
  • Cycle length: Every 21 days (3-week cycles)
  • Duration: Continue until disease progression or unacceptable toxicity

Important North American Dosing Consideration

The capecitabine dose of 1,000 mg/m² twice daily is specifically recommended for North American patients 2, 3, 4. European studies used 1,250 mg/m² twice daily, but evidence suggests North American patients experience greater toxicity with fluoropyrimidines and require lower starting doses 2, 3. The 1,000 mg/m² dose provides similar efficacy with improved tolerability.

Evidence Supporting CAPOX

CAPOX has been validated as equivalent to FOLFOX in a large randomized phase III trial of 2,034 patients, showing similar median PFS (8.0 vs 8.5 months) and establishing non-inferiority 3. Multiple guidelines confirm CAPOX as an alternative to infusional 5-FU/oxaliplatin combinations with similar activity and safety 5, 6, 7, 8, 9.

Addition of Bevacizumab

Consider adding bevacizumab 7.5 mg/kg IV on Day 1 of each cycle 10. The combination of CAPOX plus bevacizumab is supported by:

  • Level I, Grade A evidence for improved outcomes 5, 8
  • FDA approval for first-line metastatic colorectal cancer 10
  • Demonstrated improvements in PFS when bevacizumab added to CAPOX (though more modest than with other regimens) 10

Critical bevacizumab precautions:

  • Increased arterial thrombotic events, especially in patients ≥65 years
  • Requires 6-week interval before elective surgery and 6-8 weeks post-operatively before restarting
  • Contraindicated with wound healing issues

Oxaliplatin Management Strategy

Plan for oxaliplatin discontinuation after 3-4 months (or 6 cycles) to prevent cumulative neurotoxicity 2, 3, 1:

  • Continue capecitabine ± bevacizumab as maintenance therapy
  • Discontinue oxaliplatin earlier if ≥Grade 2 neuropathy develops
  • Can reintroduce oxaliplatin if discontinued for neurotoxicity (not progression) and symptoms resolve

This stop-and-go approach maintains disease control while minimizing long-term neurological sequelae 3.

Dose Modifications for Toxicity

Per FDA labeling 1:

Peripheral neuropathy:

  • Persistent Grade 2: Reduce oxaliplatin to 75 mg/m²
  • Persistent Grade 3: Consider discontinuing oxaliplatin
  • Grade 4: Permanently discontinue oxaliplatin

Myelosuppression (Grade 3-4 neutropenia or thrombocytopenia):

  • Delay next cycle until ANC ≥1.5 × 10⁹/L and platelets ≥75 × 10⁹/L
  • Reduce oxaliplatin to 75 mg/m²

Gastrointestinal toxicity (Grade 3-4):

  • After recovery, reduce oxaliplatin to 75 mg/m²

Alternative Considerations

If patient cannot tolerate oxaliplatin or has contraindications:

  • FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab is equally effective 3, 9
  • For frail patients: Consider fluoropyrimidine monotherapy ± bevacizumab 3, 9

For RAS wild-type, left-sided tumors: Anti-EGFR antibodies (cetuximab or panitumumab) can be combined with FOLFOX or FOLFIRI, though not with bevacizumab 9, 10.

For aggressive disease requiring maximum response (e.g., potentially resectable metastases): Consider FOLFOXIRI ± bevacizumab in fit patients with good performance status 9, 10.

Monitoring Requirements

  • CT imaging every 2 months to assess for conversion to resectability 11
  • Monitor for hand-foot syndrome (occurs in ~31% with capecitabine) 3
  • Assess for neurotoxicity before each cycle
  • CBC before each cycle

Common Pitfalls to Avoid

  1. Do not use calcium/magnesium infusions to prevent oxaliplatin neuropathy—proven ineffective 3
  2. Do not combine bevacizumab with anti-EGFR antibodies—increases toxicity without benefit 2, 8, 9
  3. Do not continue oxaliplatin beyond 6 months in responding patients—cumulative neurotoxicity outweighs benefit
  4. Monitor closely during first cycle for capecitabine toxicity and adjust dose as needed 2, 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.